Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy

MG Lawrence; D Obinata; S Sandhu; LA Selth; SQ Wong; LH Porter; N Lister; D Pook; CJ Pezaro; DL Goode; RJ Rebello; AK Clark; M Papargiris; J Van Gramberg; AR Hanson; P Banks; H Wang; B Niranjan; S Keerthikumar; S Hedwards; A Huglo; R Yang; C Henzler; Y Li; F Lopez-Campos; E Castro; R Toivanen; A Azad; D Bolton; J Goad; J Grummet; L Harewood; J Kourambas; N Lawrentschuk; D Moon; DG Murphy; S Sengupta; R Snow; H Thorne; C Mitchell; J Pedersen; D Clouston; S Norden; A Ryan; SM Dehm; WD Tilley; RB Pearson; RD Hannan; M Frydenberg; L Furic; RA Taylor; GP Risbridger

Journal article

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy

MG Lawrence, D Obinata, S Sandhu, LA Selth, SQ Wong, LH Porter, N Lister, D Pook, CJ Pezaro, DL Goode, RJ Rebello, AK Clark, M Papargiris, J Van Gramberg, AR Hanson, P Banks, H Wang, B Niranjan, S Keerthikumar, S Hedwards Show all

European Urology | Published : 2018

DOI: 10.1016/j.eururo.2018.06.020

Abstract

Background: The intractability of castration-resistant prostate cancer (CRPC) is exacerbated by tumour heterogeneity, including diverse alterations to the androgen receptor (AR) axis and AR-independent phenotypes. The availability of additional models encompassing this heterogeneity would facilitate the identification of more effective therapies for CRPC. Objective: To discover therapeutic strategies by exploiting patient-derived models that exemplify the heterogeneity of CRPC. Design, setting, and participants: Four new patient-derived xenografts (PDXs) were established from independent metastases of two patients and characterised using integrative genomics. A panel of rationally selected d..

View full abstract

University of Melbourne Researchers

Shahneen Sandhu Author

Stephen Wong Author

David Goode Author

Richard Rebello Author

Related Projects (3)

BIOINFORMATICS APPROACHES TO STUDYING CANCER GENETICS AND TUMOUR EVOLUTION

Chemotherapy often fails because some of the cells in tumour evolve resistance to the drugs the patient is given, causing relapse. We study ..

A NOVEL STRATEGY FOR TARGETING CASTRATE-RESISTANT PROSTATE CANCER

Modern drugs for advanced prostate cancer are based on starving the tumour of hormones. However, tumours either escape this treatment or are..

THE KATHLEEN CUNINGHAM FOUNDATION CONSORTIUM FOR RESEARCH INTO FAMILIAL BREAST CANCER (KCONFAB)

Grants

Awarded by National Cancer Institute

Funding Acknowledgements

This work was supported by funding from the National Health and Medical Research Council of Australia (fellowships to M.G.L. 1035721, G.P.R. 1102752, D.L.G. 1052904, and R.T. 1090204; project grant 1121057 to W.D.T., L.A.S., G.P.R., and R.T.; project grant 1138242 to G.P.R., W.D.T., L.F., S.S., A.A., L.A.S., and M.G.L.), Cancer Australia (project grant 1084546 to L.F., R.D.H., R.B.P, S.S., and G.P.R), the Department of Health and Human Services acting through the Victorian Cancer Agency (Early Career Seed grant to M.G.L. 13033, fellowships to L.F. MCRF16007, R.A.T. MCRF15023, CAPTIV Program), U.S. National Institutes of Health (R01CA174777 to S.M.D.), Prostate Cancer Foundation of Australia fellowship to S.S. (YIA2013), the Prostate Cancer Foundation (Young Investigator Awards to L.A.S., E.C., and R.Y.), Movember-Prostate Cancer Foundation (Challenge Award to S.M.D.), the CASS Foundation (Medical Science grant to M.L. 7139), MINIECO (Juan de la Cierva' fellowship to E.C. IJCI-2014-19129), the Peter MacCallum Cancer Foundation, the EJ Whitten Foundation, the Peter and Lyndy White Foundation, and TissuPath Pathology.